Dbv technologies completes screening for the vitesse phase 3 clinical trial

ChÂtillon, france, september 23, 2024 dbv technologies completes screening for the vitesse phase 3 clinical trial in q3 2024, dbv exceeded its recruitment goal and successfully closed the screening process for the vitesse phase 3 study evaluating the viaskin ® peanut patch in peanut allergic children ages 4 – 7 years old topline results of vitesse data are expected by q4 2025 dbv technologies (euronext: dbv – isin: fr0010417345 – nasdaq stock market: dbvt), a clinical-stage biopharmaceutical company, today announced that patient screening is complete for the phase 3 trial, vitesse ( v iaskin peanut i mmunotherapy t rial to e valuate s afety, s implicity and e fficacy), using the modified viaskin peanut patch in children ages 4 – 7 years old with peanut allergy. “we are thrilled to have reached this significant milestone,” said dr. pharis mohideen, chief medical officer of dbv technologies.
DBVT Ratings Summary
Quant
DBVT Quant Ranking
Sector
Industry
Quant Rating
Quant Score